RxDoctor Payments Data

Michael Mikita

Physician Assistant · Warren, PANPI 1902454804

Payments from drug & device makers

$1,626in general payments, 2019–2025

Across 74 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$315
  • AbbVie$254
  • Astellas Pharma US Inc$202
  • Myriad Genetic Laboratories, Inc.$182
  • Johnson & Johnson$109
  • Teleflex LLC$79
  • plus $485 from 16 others

What the payments were for

  • Food & beverage$1,45890%
  • Education$16810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,626 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,336
Medicare patients
136
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron350$229,063
GemtesaVibegron165$113,588
Mirabegron ErMirabegron27$13,674
Tamsulosin Hcl622$8,280
Trospium Chloride112$5,936
Silodosin39$5,030
Solifenacin Succinate129$4,750
Fosfomycin Tromethamine13$4,259
Testosterone Cypionate81$4,065
Alfuzosin Hcl ErAlfuzosin Hcl162$3,694
Oxybutynin Chloride ErOxybutynin Chloride208$3,648
Cephalexin402$3,087
Tolterodine Tartrate ErTolterodine Tartrate23$3,048
Testosterone24$3,026
NitrofurantoinNitrofurantoin Macrocrystal39$1,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$202$229,063350 claims
Sumitomo Pharma America, Inc.Gemtesa$315$113,588165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Warren

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →